Abstract
Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron, the fifth VOC to be described, harbours 30 amino acid mutations in spike including 15 in the receptor-binding domain. Here, we demonstrate substantial evasion of neutralisation by Omicron in vitro using sera from vaccinated individuals. Importantly, these data are mirrored by a substantial reduction in real-world vaccine effectiveness that is partially restored by booster vaccination. We also demonstrate that Omicron does not induce cell syncytia and favours a TMPRSS2-independent endosomal entry pathway. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The EVADE study is supported by HDR-UK (E.C.T). COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute (G.M., R.M.B., D.L.R., E.C.T.). The COVID-19 DeplOyed VaccinE (DOVE) study is funded by the Medical Research Council core award (MCUU1201412) and COG-UK. We acknowledge the support of the G2P-UK National Virology Consortium (MR/W005611/1) funded by the UKRI (M.P.,E.C.T.). A.F., J.H., R.O and D.L.R acknowledge the MRC (MC_UU_12014/12) and DLR the Wellcome Trust (220977/Z/20/Z). W.T.H. is funded by the MRC (MR/R024758/1 and MR/W005611/1). N.L. and B.J.W. were funded by the Biotechnology and Biological Sciences Research Council (BBSRC, BB/R004250/1), G.T. was funded by the Department of Health and Social Care (DHSC, BB/R019843/1). J.G. is supported by a Sir Henry Dale Fellowship from the Wellcome Trust and Royal Society (107653/Z/15/A) and by the Medical Research Council (MC_UU_12014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The North West Central Liverpool Research Ethics Committee/IRB gave ethical approval for the DOVE study (21/NW/0073). Informed written consent was obtained for all participants. In addition, the NHS GG&C SafeHaven gave derogated ethical approval for the use of anonymised population data (GSH/21/IM/001). NHS Caldicott approval was also obtained for the use of anonymised clinical data. Lothian biorepository ethical approval was given for the isolation of virus from clinical samples (reference 10/S1402/33).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ Full list of consortium names and affiliations are listed in the Supplementary information.
Figures have been condensed into 4 figures and the panel 4C data on vaccine effectiveness has been updated with more recent information. The text has been modified to reduce to 4 rather than 6 figures.
Data Availability
All sequence data are published via GISAID. All data produced in the present study are available upon reasonable request to the authors other than identifying clinical information.
